February 1, 2018 / 9:40 PM / 3 months ago

BRIEF-Puma Biotechnology And Canbridge Life Sciences Enter Into Exclusive Licensing Agreement

Feb 1 (Reuters) - Puma Biotechnology Inc:

* PUMA BIOTECHNOLOGY AND CANBRIDGE LIFE SCIENCES ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN GREATER CHINA

* PUMA BIOTECHNOLOGY - CANBRIDGE WILL DEVELOP AND COMMERCIALIZE NERLYNX (NERATINIB) IN MAINLAND CHINA, TAIWAN, HONG KONG, AND MACAU

* PUMA BIOTECHNOLOGY SAYS WILL RECEIVE UPFRONT PAYMENT OF $30 MILLION

* PUMA BIOTECHNOLOGY - CO TO GET UPFRONT PAYMENT OF $30 MILLION AND POTENTIAL MILESTONE PAYMENTS TOTALING UP TO $40 MILLION

* PUMA BIOTECHNOLOGY - TO GET SIGNIFICANT DOUBLE-DIGIT ROYALTIES ON NERLYNX SALES IN GREATER CHINA AND POTENTIAL MILESTONE PAYMENTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below